Oliver Sartor

发表

Maßnahmen zum Schutz vor Carbon Leakage für CO₂-intensive Materialien im Zeitraum nach 2020

Karsten Neuhoff, William Acworth, Roland Ismer, 2015 .

Energy intensive industries carbon control & competitiveness post 2020 – the cement report. Climate strategies.

Jean-Pierre Ponssard, Arjan van Rooij, Karsten Neuhoff, 2013 .

Tracking sectoral progress in the deep decarbonisation of energy systems in Europe

Pantelis Capros, Katharina Knoop, Manfred Fischedick, 2017 .

Modernisierung und Innovation bei CO₂-intensiven Materialien: Lehren aus der Stahl- und Zementindustrie

Jean-Pierre Ponssard, Karsten Neuhoff, Oliver Sartor, 2015 .

Steel Report: Carbon Control Post 2020 in Energy Intensive Industries

Karsten Neuhoff, William Acworth, Roland Ismer, 2014 .

Energie- und Klimapolitik: Europa ist nicht allein

Karsten Neuhoff, William Acworth, Oliver Sartor, 2014 .

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.

David Green, Andrew D. Zelenetz, Oliver Sartor, 2009, Blood.

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

Thomas Wiegel, Colin C Pritchard, Stefano Fanti, 2018, European urology.

Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.

William Berry, Oliver Sartor, J Alfred Witjes, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.

Sten Nilsson, Oliver Sartor, John Logue, 2014, The Lancet. Oncology.

The Research on Adverse Drug Events and Reports (RADAR) project.

Matthew H Samore, Jonathan R Nebeker, Kenneth R Carson, 2005, JAMA.

The Gleason Score: A Significant Biologic Manifestation of Prostate Cancer Aggressiveness On Biopsy

David G. Bostwick, Oliver Sartor, D. Bostwick, 2001 .

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

Oliver Sartor, Susan Halabi, Lawrence H Schwartz, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular and Cellular Pathobiology Interleukin-17 Promotes Formation and Growth of Prostate Adenocarcinoma in Mouse Models

Oliver Sartor, Jonathan Melamed, Leann Myers, 2012 .

Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?

Steven Hirschfeld, Jonathan R Nebeker, Kenneth R Carson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Berberine Suppresses Androgen Receptor Signaling in Prostate Cancer

Oliver Sartor, Jing Li, Bo Cao, 2011, Molecular Cancer Therapeutics.

Unmet needs in the prediction and detection of metastases in prostate cancer.

Oliver Sartor, Michael W Kattan, M. Kattan, 2013, The oncologist.

Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines.

Oliver Sartor, Richard K Valicenti, Mack Roach, 2013, International journal of radiation oncology, biology, physics.

Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities.

Oliver Sartor, John Trachtenberg, Michel Rossignol, 2007, The Journal of urology.

Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data.

Thomas Yu, Tapio Pahikkala, Antti Airola, 2017, The Lancet. Oncology.

Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project.

Jonathan R Nebeker, Oliver Sartor, Dennis W Raisch, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.